Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis

Vadim Pivniouk, Joao A. Gimenes-Junior, Peace Ezeh, Ashley Michael, Oksana Pivniouk, Seongmin Hahn, Sydney R. VanLinden, Sean P. Malone, Amir Abidov, Dayna Anderson, Justyna Gozdz, Avery DeVries, Fernando D. Martinez, Christian Pasquali, Donata Vercelli

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Background: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma. Objectives: We sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route. Methods: Different strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85–treated dendritic cells protect allergen-sensitized, OM-85–naive mice against asthma. Results: Airway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen–induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85–induced asthma protection. Conclusions: We provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27- to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.

Original languageEnglish (US)
Pages (from-to)943-956
Number of pages14
JournalJournal of Allergy and Clinical Immunology
Volume149
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • Bacterial lysate
  • OM-85
  • adaptive immunity
  • airway compartment
  • allergic inflammation
  • asthma
  • innate immunity
  • intranasal route
  • microbial interventions

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis'. Together they form a unique fingerprint.

Cite this